Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;6(6):1140-1148.
doi: 10.1002/ehf2.12551. Epub 2019 Dec 28.

Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'

Markus S Anker  1 , Sara Hadzibegovic  1 , Alessia Lena  1 , Yury Belenkov  2 , Jutta Bergler-Klein  3 , Rudolf A de Boer  4 , Dimitrios Farmakis  5   6 , Stephan von Haehling  7 , Zaza Iakobishvili  8 , Christoph Maack  9 , Radek Pudil  10 , Hadi Skouri  11 , Alain Cohen-Solal  12 , Carlo G Tocchetti  13 , Andrew J S Coats  14 , Petar M Seferović  15 , Alexander R Lyon  16 ; Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology
Affiliations

Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'

Markus S Anker et al. ESC Heart Fail. 2019 Dec.

Abstract

While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.

Keywords: Cancer; Cardiotoxicity; Heart failure.

PubMed Disclaimer

Conflict of interest statement

M.S.A. reports receiving personal fees from Servier. The UMCG, which employs R.A.dB. has received research grants and/or fees from AstraZeneca, Abbott, Bristol‐Myers Squibb, Novartis, Novo Nordisk, and Roche. R.A.dB. received speaker fees from Abbott, AstraZeneca, Novartis, and Roche. D.F. has received speaker honoraria, consultancy fees, and/or travel grants from Abbott, Boehringer‐Ingelheim, Daiichi‐Sankyo, Menarini, Novartis, Pfizer, Roche, and Servier. S.vH. has been a paid consultant to BRAHMS/Thermo Fisher, Chugai, Helsinn, Boehringer Ingelheim, Grünenthal, Novartis, Roche, and Vifor. Z.I. reports lecture fees from Novartis, Pfizer, Boehringer Ingelheim, Bayer, Novo Nordisk, Astra Zeneca, and Eli Lilly. C.M. received personal fees from Servier, Boehringer Ingelheim, AstraZeneca, Bayer, Bristol‐Myers Squibb, Novartis, Berlin Chemie, and Daiichi Sankyo. H.S. received speaker honoraria from Servier, Novartis, Boehringer, and Astra Zeneca. A.C.S. received personal fees (honoraria, grants, and travel expenses) from Novartis, Servier, Vifor, MSD, Astra Zeneca, Abbott, and Cytokinetics. C.G.T. was funded by a “Riceca di Ateneo/Federico II University” grant. A.J.S.C. has received fees from Astra Zeneca, Bayer, Menarini, Novartis, Nutricia, Servier, Vifor, Actimed, Cardiac Dimensions, CVRx, Enopace, Faraday, Gore, Respicardia, Stealth Peptides, and V‐Wave. A.R.L. has received speaker, advisory board or consultancy fees, and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssens‐Cilag Ltd, Clinigen Group, Eli Lily, Eisai, Bristol Myers Squibb, Ferring Pharmaceuticals, and Boehringer Ingelheim. All other authors report no conflict of interest.

Figures

Figure 1
Figure 1
Aetiology of cardiovascular disease in cancer patients.
Figure 2
Figure 2
Diagnostic methods for early detection of cardiotoxicity.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOSCAN 2012. Int J Cancer 2015; 136: E359–E386. - PubMed
    1. de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013; 22: 561–570. - PMC - PubMed
    1. Na SY, Sung JY, Chang JH, Kim S, Lee HH, Park YH, Chung W, Oh KH, Jung JY. Chronic kidney disease in cancer patients: an independent predictor of cancer‐specific mortality. Am J Nephrol 2011; 33: 121–130. - PubMed
    1. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010; 23: 253–262. - PMC - PubMed
    1. Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan‐Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Liver dysfunction in chronic lymphocytic leukemia: prevalence, outcomes, and pathological findings. Am J Hematol 2017; 92: 1362–1369. - PMC - PubMed